Santhi Voora is a Nephrology physician affiliated with University of Southern California. OpenAlex indexes 15 publications with 210 citations (h-index 4); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1520 San Pablo St Ste 1000
Los Angeles, CA 90033
Telephone
323-442-5100Provider last certified this registry record 29 Sept 2020.
Clinical trials
- Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
Sponsor: University of Southern California
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kaneka Medical America LLCProgram year20242 payments
- Merck Sharp & Dohme LLCProgram year20241 payment
- Veloxis Pharmaceuticals, Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
39.4%Angiotensin receptor blocker (ARB)10.7%Losartan Potassium85%Telmisartan15%Part D<11 patientsStatin8.3%Atorvastatin Calcium84%Pravastatin Sodium16%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
23.9%H2 blocker6.3%Famotidine100%Part D≥29 patientsCorticosteroid6.3%Prednisone100%Part D≥39 patients+ 5 more classes in this area
Anti-infectives
11.2%Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.9%Valganciclovir Hcl100%Part D≥29 patientsShort-acting sulfonamides3.9%Sulfamethoxazole-Trimethoprim100%Part D≥20 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Management of the kidney transplant recipient in the intensive care unit
Current Opinion in Critical Care
2023 - Clinical Course of a Kidney Transplant Recipient with Epstein-Barr Virus Viremia Treated with Maribavir
Journal of the American Society of Nephrology
2023 - Concern for Donor-Derived Candidiasis Causing a Mycotic Aneurysm in the Transplanted Renal Artery
Journal of the American Society of Nephrology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”